Oppenheimer Lowers Evolent Health Price Target to $6
Oppenheimer lowered the firm's price target on Evolent Health to $6 from $12 and keeps an Outperform rating on the shares following the company's Q4 earnings release and newly issued guidance. The firm is lowering FY2026/2027 EPS estimates and issuing an initial FY2028 EPS estimate. Overall, Oppenheimer believes the more conservative posture toward reserves and the upside to margins from the significant new business, sets the company up for outsized growth in the coming years.
